Microbiome Competitors

Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.

Synthego is a CRISPR solutions provider that enables the acceleration of life science research and development in the pursuit of improved human health. Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments. At Synthego, our values define who we are and how we work together to shape the future of science. Ingenuity drives us to innovate and solve complex challenges in groundbreaking ways. Collaboration fuels our success, as we believe the best ideas come from diverse perspectives working together. Kindness shapes our workplace culture, fostering mutual respect and care for one another. Empowerment inspires every team member to take initiative, grow, and make meaningful contributions. Integrity forms the foundation of everything we do, ensuring trust, transparency, and excellence guide our actions. We believe that fostering an environment of belonging is essential to driving innovation and collaboration. Through our Diversity Network Association (DNA), we actively amplify diverse voices, champion equity, and create spaces where inclusivity thrives. These principles are not just policies or initiatives; they’re integrated into our DNA and guide how we work together every day. By weaving diversity, equity, and inclusion into the fabric of our identity, we strengthen our team, inspire new ideas, and ensure everyone can contribute meaningfully to shaping the future of science.

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ .